Company Profile

Vasade Biosciences Inc (AKA: VATNER)
Profile last edited on: 8/30/2023      CAGE: 46YB1      UEI: J66DCHJSKWA4

Business Identifier: Novel inhibitors of AC5: cardioprotection against myocardial infarction and congestive heart failure
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

675 Us Highway One
North Brunswick, NJ 08902
   (732) 729-6215
Location: Multiple
Congr. District: 12
County: Middlesx

Public Profile

With strong ties to the Cardiovascular Research Institute, UMDNJ-New Jersey Medical School, Newark, Vasade Biosciences, Inc., is a biotechnology company engaged in the pre-clinical discovery and development of cardioprotective and vascular protective molecules, drugs, and devices for the prevention, treatment, and management of cardiovascular disease. Vasade is investigating inhibitors of type 5 adenylyl cyclase (AC5) that hold promise as alternatives to ß-blockers as cardioprotective agents during heart failure progression. Following targeted screening of small molecule compounds, Vasade and collaborators identified selective type 5 adenylyl cyclase inhibitors and preliminary results demonstrate a protective response in an ishemia / reperfusion mouse model of heart disease. Vasade is also actively developing inhibitors of Mammalian Sterile 20-Like Kinase 1 (Mst1) as therapeutic treatment for reducing apoptosis and cardiac deterioration associated with ischimic heart disease. The third approach Vasade is taking is the development of Mammalian Sterile 20-Like Kinase 1 (Mst1) eluting stents. The stents are proposed as a therapeutic means of inhibiting smooth muscle proliferation and restenosis that may follow angioplasty. Vasade is investigating the efficiency, toxicity, and efficacy of stents eluting a Mst1 gene targeted for expression in smooth muscle cells. Finally, Vasade is investigating increased levels of Heat Shock H11 Kinase (H11K) as a highly effective measure to protect the heart from ischemic damage. Vasade is developing gene therapy vectors for the overexpression of H11K in heart and has begun to identify small molecule activators of H11K and the H11K signalling pathway.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2023 1 NIH $252,130
Project Title: A Novel Pharmacological Inhibitor of Adenylyl Cyclase Type 5 to Treat Alzheimer's Disease
2020 2 NIH $1,560,580
Project Title: Adenylyl Cyclase Type 5 Inhibition to Treat Myocardial Infarction
2014 2 NIH $1,809,644
Project Title: Ac5 Inhibitor for Heart Failure
2012 1 NIH $167,930
Project Title: Acute Coronary Syndrome Animal Model
2011 2 NIH $1,248,989
Project Title: Prevention of cardiac cell death by Mst1 inhibitor

Key People / Management

  Stephen F Vatner -- President and Founder

  Patricio Abarzua -- Vice President of Operations

  Hongyu Qiu

  Junichi Sadoshima -- Vice President and Executive Director of Research

  Youtang Shen

  Dorothy E Vatner -- Director of Proteomic Research